Loading...
01/11 03:19
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates challenges with adjusted EPS guidance reduction, Medicaid attrition, and Marketplace business running below breakeven. The Q&A section highlights concerns over market stability, competitive positioning, and lack of clear guidance on Medicaid margins and exchange stability. Despite some positive aspects like improved SG&A ratio and cash flow, the overall sentiment is negative due to significant financial and operational uncertainties, particularly in the Marketplace and Medicaid segments. This is likely to lead to a negative stock price movement in the short term.
Adjusted EPS (Earnings Per Share) Reported at $0.50 for Q3 2025, ahead of expectations. This was driven by Medicaid HBR improvement, a positive retroactive revenue adjustment in Florida, stronger-than-expected net investment income, and a lower effective tax rate.
Medicaid HBR (Health Benefits Ratio) Improved to 93.4% in Q3 2025, better than expected. This included a $150 million positive revenue adjustment in Florida's Children's Medical Services program, of which $90 million was retroactive to Q1 and Q2 2025. Improvement was also due to rate advocacy, program changes, and fraud interventions.
Premium and Service Revenue Reported at $44.9 billion for Q3 2025. No year-over-year comparison provided.
GAAP Loss Per Share Reported at a loss of $13.50 due to a $6.7 billion non-cash goodwill impairment charge. This charge had no impact on statutory capital, cash, or adjusted EPS.
Medicaid Membership Reported at 12.7 million members as of Q3 2025, with slight attrition expected in the coming quarters.
Commercial Segment HBR Reported at 89.9% for Q3 2025, in line with expectations. This included a $2.4 billion forecast change due to marketplace morbidity and medical expense trends.
Medicare Segment HBR Reported at 94.3% for Q3 2025, reflecting typical cost patterns in Medicare Advantage and PDP. Medicare Advantage medical cost trends were elevated but consistent with expectations.
Adjusted SG&A Expense Ratio Improved to 7.0% in Q3 2025 from 8.3% in Q3 2024, driven by growth in PDP revenue and expense leveraging.
Investment and Other Income Increased by $79 million in Q3 2025 compared to Q2 2025, driven by gains and temporarily higher cash balances.
Cash Flow from Operations Reported at $1.4 billion for Q3 2025, primarily driven by net earnings and timing of pass-through payments.
Medicaid HBR improvement: Achieved 150 basis points of sequential improvement in Medicaid HBR, aided by improved revenue from Florida Children's Medical Services contract and fundamental improvements like rate advocacy, program changes, and fraud interventions.
Marketplace membership: Ended the quarter with 5.8 million members, slightly better than expectations. Positioned for 2026 margin expansion with revised rates and additional actions to minimize margin impact.
Medicare Advantage and PDP: Performed in line with expectations. Medicare Advantage is on track for breakeven in 2027, and PDP positioning is strong for 2026.
Medicaid rate adjustments: Finalized 2025 composite rate adjustment to roughly 5.5%, higher than the 5% expected earlier.
Marketplace repricing: Revised rates for 2026 in states covering 95% of current membership, accounting for morbidity, trend, and policy impacts.
SG&A expense ratio: Improved to 7.0% in Q3 from 8.3% last year, driven by leveraging expenses over higher revenues and disciplined management.
Investment income: Stronger than expected in Q3, driven by one-time gains. Flexibility provided in guidance to take investment losses in Q4 for 2026 trajectory improvement.
Medicaid fraud interventions: Progress in New York with termination of a provider group engaged in suspicious billing practices, leading to cost savings.
Medicare dual eligible populations: Launched enhanced integrated duals model across 8 states, aligning with the transition to integrated D-SNPs effective January 1, 2026.
Medicaid Cost Trends: Behavioral health, home health services, and high-cost drugs are driving above-baseline trends, with behavioral health accounting for 50% of the excess costs. Despite some progress, these trends remain a challenge to Medicaid profitability.
Marketplace Medical Costs: Increased medical cost pressure in September and uncertainty around eAPTC expiration could lead to higher utilization and financial strain. An additional $75 million provision was added to account for potential volatility.
Regulatory and Policy Uncertainty: Uncertainty surrounding eAPTC expiration and Medicaid rate adjustments creates challenges in forecasting and financial planning. Congressional decisions on tax credits remain unresolved.
Fraud, Waste, and Abuse: Significant Medicaid cost pressures in states like New York and Florida due to fraud and abuse. While some progress has been made, these issues continue to impact financial performance.
Medicare Cost Trends: Elevated medical cost trends in Medicare Advantage and PDP segments, with some containment through risk corridors. However, these trends remain a concern for long-term profitability.
Goodwill Impairment: A $6.7 billion non-cash goodwill impairment charge was recorded, reflecting a significant write-down of assets and impacting GAAP results.
Investment Income Volatility: Q3 investment income gains are not expected to recur, and potential losses may be harvested in Q4 to improve 2026 income trajectory.
Operational and Strategic Execution: Challenges in achieving Medicaid margin improvement and Medicare breakeven goals by 2027 require ongoing operational adjustments and strategic focus.
Adjusted EPS Forecast for 2025: Centene has increased its adjusted EPS forecast for 2025 to at least $2, up from the previous forecast of $1.75 per share.
Marketplace Business Outlook: Centene expects meaningful margin improvement in its Marketplace business in 2026 due to pricing actions that account for baseline morbidity, trend, eAPTC expiry, and program integrity impacts. The company has priced its products to support year-over-year margin improvement even if eAPTCs expire.
Medicaid Business Projections: Centene expects a 2025 Medicaid composite rate adjustment of roughly 5.5%, up from the previously targeted 5%. The company anticipates maintaining profitability consistent with its 2025 outlook into 2026.
Medicare Segment Outlook: Centene aims for breakeven pretax margin in its Medicare Advantage business by 2027. The company expects margin recovery to take priority over membership growth in 2026.
Investment Income and Tax Rate: Centene may take investment losses in Q4 2025 to improve the trajectory of investment income in 2026. The company also anticipates a higher tax rate in 2026, which will act as a headwind.
Operational Improvements and Margin Expansion: Centene plans to focus on operational improvements, efficiency gains, and margin expansion to drive EPS growth in 2026.
The selected topic was not discussed during the call.
The earnings call summary indicates challenges with adjusted EPS guidance reduction, Medicaid attrition, and Marketplace business running below breakeven. The Q&A section highlights concerns over market stability, competitive positioning, and lack of clear guidance on Medicaid margins and exchange stability. Despite some positive aspects like improved SG&A ratio and cash flow, the overall sentiment is negative due to significant financial and operational uncertainties, particularly in the Marketplace and Medicaid segments. This is likely to lead to a negative stock price movement in the short term.
The earnings call summary indicates strong financial performance with revenue growth, strategic Medicaid and Medicare wins, and operational efficiency improvements. The Q&A session highlighted management's confidence in future earnings and margin improvements, despite some market challenges. The positive sentiment is further supported by the increased revenue guidance and optimistic outlook for 2026. Although there are uncertainties regarding market contractions and Medicaid adjustments, the overall outlook is positive, with expected higher earnings and strategic measures in place to address potential risks.
The earnings call presents a mixed picture. Financial performance shows some strength with increased EPS and revenue, but there are concerns about rising costs, regulatory risks, and potential Medicaid benefit cuts. The Q&A section reveals uncertainties about marketplace dynamics and management's vague responses on key issues. Although there is an increase in 2025 revenue guidance, the lack of a share repurchase program and operational challenges in Medicare Advantage temper optimism. Overall, the sentiment is balanced, leading to a neutral prediction for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
